Resources

Following our webinar, The Greatest Hits: A Beginner's Guide to High-Quality Starting Points for Drug Discovery, Symeres experts answer audience questions on hit discovery, screening strategy and lead optimisation. Explore insights on carbohydrate scaffolds, natural products, library design and how the SymeGold collection supports successful drug discovery programmes.

Most drug candidates fail due to pharmacokinetic and safety issues that could have been identified earlier. This Q&A explores how integrated ADME-Tox testing helps teams detect and address these risks during drug discovery.

A synthetic route that performs well at gram scale can fail abruptly during scale-up, where heat transfer, impurity pathways and operational variability expose hidden weaknesses. This article outlines three early red flags that signal a route may not withstand manufacturing conditions — and how identifying them early can prevent costly rework.

Lead optimization often stalls not because of a lack of data, but because the available data has not been translated into clear decisions. This article explores how disciplined, decision-led lead optimization strategies help discovery teams reduce uncertainty, focus experiments, and progress programs more predictably.

This article explores how disciplined, hypothesis-driven lead optimization can produce clearer SAR, reduce development risk, and help small-molecule programs progress more efficiently toward a clinical candidate.

A clean pharmacokinetics profile is often seen as a green light. But in practice, overly tidy PK data can hide analytical artefacts, non-linear behaviour, or poorly understood clearance mechanisms that surface later at significant cost.

Communication breakdowns rarely start as major problems, but small gaps in coordination can quietly slow progress and erode trust in CDMO partnerships.

Part 4: When “Too Busy” Becomes a Business Risk Even the most capable CDMO cannot deliver high-quality work if it is stretched too thin. As demand for outsourcing continues to rise across the life sciences sector, many CDMOs are operating near or beyond capacity. For pharma and biotech companies, this creates a silent but serious […]

Part 3: Could Regulatory Misalignment Be Delaying Your Submission? A CDMO can have the best scientists, excellent facilities, and strong technical execution, yet still fall short when it comes to regulatory alignment. This disconnect between scientific performance and regulatory readiness is one of the most damaging red flags in drug development as it could delay […]

Part 2: Why “Scale-Up” Isn’t Just a Bigger Batch Transitioning a process from discovery scale to GMP manufacturing is almost never straightforward. What runs smoothly at 100 milligrams in the lab can behave very differently at the kilogram scale. Yet too many programs falter because the complexity of this transition is underestimated or treated as […]

No drug development program runs perfectly. Chemistry misbehaves, funding shifts, and timelines tighten. But what defines a reliable partner is how they respond. O.N.E Symeres is the framework we use to keep projects moving through uncertainty: openness, nimbleness, and expertise.

Part 1: Is an Undefined Scope Putting Your Project at Risk? Selecting the right CDMO is one of the most important decisions in drug development. Yet even experienced biotechs and pharma companies can find themselves trapped in projects where the initial excitement gives way to frustration, and one of the most common culprits is a […]